PE20150889A1 - Protozoo modificado que expresa al menos dos proteinas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y metodos - Google Patents

Protozoo modificado que expresa al menos dos proteinas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y metodos

Info

Publication number
PE20150889A1
PE20150889A1 PE2015000436A PE2015000436A PE20150889A1 PE 20150889 A1 PE20150889 A1 PE 20150889A1 PE 2015000436 A PE2015000436 A PE 2015000436A PE 2015000436 A PE2015000436 A PE 2015000436A PE 20150889 A1 PE20150889 A1 PE 20150889A1
Authority
PE
Peru
Prior art keywords
surface proteins
vsp
variable surface
modified
protozoo
Prior art date
Application number
PE2015000436A
Other languages
English (en)
Inventor
Hugo Daniel Lujan
Original Assignee
Consejo Nac Invest Cient Tec
Univ Catolica De Cordoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec, Univ Catolica De Cordoba filed Critical Consejo Nac Invest Cient Tec
Publication of PE20150889A1 publication Critical patent/PE20150889A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invencion describe un procedimiento para purificar el repertorio total de proteinas de superficie variable (VSP) de un protozoo parasito Giardia lamblia modificado en donde los genes Dicer, ARN polimerasa RNA dependiente (RdRP) o ambos, han sido silenciados mediante ingenieria genetica usando ARN antisentido, de esta manera comprendiendo la expresion simultanea en su superficie de multiples proteinas de superficie variables, caracterizado porque comprende: a) Unir un anticuerpo que reconoce la secuencia de aminoacidos CRKGA de las VSP a un soporte solido; b) Contactar el soporte solido con un protozoo parasito Giardia lamblia; y c) Separar el repertorio total de proteinas de superficie variable (VSP)
PE2015000436A 2008-12-02 2009-12-02 Protozoo modificado que expresa al menos dos proteinas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y metodos PE20150889A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11905808P 2008-12-02 2008-12-02

Publications (1)

Publication Number Publication Date
PE20150889A1 true PE20150889A1 (es) 2015-06-07

Family

ID=42233679

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001143A PE20110942A1 (es) 2008-12-02 2009-12-02 Protozoo modificado que expresa multiples proteinas variables de superficie (vsp), composicion inmunogenica que lo comprende y procedimientos
PE2015000436A PE20150889A1 (es) 2008-12-02 2009-12-02 Protozoo modificado que expresa al menos dos proteinas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y metodos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001143A PE20110942A1 (es) 2008-12-02 2009-12-02 Protozoo modificado que expresa multiples proteinas variables de superficie (vsp), composicion inmunogenica que lo comprende y procedimientos

Country Status (18)

Country Link
US (1) US9463229B2 (es)
EP (1) EP2364156B1 (es)
JP (3) JP2012510286A (es)
CN (1) CN102281884B (es)
AR (1) AR074458A1 (es)
AU (1) AU2009323734B2 (es)
BR (1) BRPI0917075B1 (es)
CA (1) CA2745470C (es)
CL (2) CL2011001309A1 (es)
CO (1) CO6390115A2 (es)
CR (1) CR20110377A (es)
EC (1) ECSP11011171A (es)
ES (1) ES2667773T3 (es)
MX (2) MX351579B (es)
NZ (2) NZ604943A (es)
PE (2) PE20110942A1 (es)
PT (1) PT2364156T (es)
WO (1) WO2010064204A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512288A (en) * 1992-12-04 1996-04-30 University Technologies International, Inc. Giardia vaccine
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
JP2000083677A (ja) * 1998-09-17 2000-03-28 Bayer Ltd ダニワクチン
GB0000474D0 (en) * 2000-01-10 2000-03-01 Inal Jameel M Receptor

Also Published As

Publication number Publication date
CL2018002834A1 (es) 2019-04-05
US9463229B2 (en) 2016-10-11
AR074458A1 (es) 2011-01-19
PE20110942A1 (es) 2011-12-30
EP2364156A2 (en) 2011-09-14
PT2364156T (pt) 2018-04-24
NZ593106A (en) 2013-05-31
MX351579B (es) 2017-10-20
JP2012510286A (ja) 2012-05-10
ECSP11011171A (es) 2011-09-30
JP2018024700A (ja) 2018-02-15
US20120093871A1 (en) 2012-04-19
JP6793621B2 (ja) 2020-12-02
CN102281884B (zh) 2015-09-30
WO2010064204A3 (en) 2010-12-02
ES2667773T3 (es) 2018-05-14
JP2016000045A (ja) 2016-01-07
CA2745470C (en) 2018-09-25
BRPI0917075A2 (pt) 2016-08-02
EP2364156B1 (en) 2018-01-31
AU2009323734B2 (en) 2016-06-30
CL2011001309A1 (es) 2012-03-16
CO6390115A2 (es) 2012-02-29
NZ604943A (en) 2014-08-29
MX2011005815A (es) 2011-09-30
WO2010064204A2 (en) 2010-06-10
CA2745470A1 (en) 2010-06-10
CR20110377A (es) 2011-10-20
CN102281884A (zh) 2011-12-14
AU2009323734A1 (en) 2010-06-10
BRPI0917075B1 (pt) 2019-11-12

Similar Documents

Publication Publication Date Title
ECSP12011685A (es) Inmunoconjugados dirigidos
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
WO2006081546A3 (en) Inhibitor nucleic acids
AR047897A1 (es) Composiciones y metodos que usan interferencia de arn para el control de nematodos
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
AR061685A1 (es) Plantas de cultivo transgenicas con mayor tolerancia al estres
CR10290A (es) Metodos para reducir la aglomeracion de proteina
CL2013003053A1 (es) Compuesto que comprende un oligonucleotido modificado que consiste en de 10 a 30 nucleósidos unidos y definidos por un grupo de secuencias específicas; composicion que comprende dicho compuesto; uso para tratar enfermedades relacionadas con el virus de la hepatitis b (vhb).
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
WO2004035765A3 (en) Double-stranded rna structures and constructs, and methods for generating and using the same
ECSP066559A (es)
BRPI0708771B8 (pt) anticorpos anti-5t4, conjugado de fármaco/ anticorpo para liberação de fármaco, usos dos mesmos e ácido nucléico isolado codificando uma região variável de cadeias pesada e leve anti-5t4
WO2007145612A8 (en) Paired end sequencing
CR20110118A (es) Tratamiento de enfermedades autoinmunes e inflamatorias
EA200800837A1 (ru) Иммуностимулирующая одноцепочечная рибонуклеиновая кислота с фосфодиэфирным остовом
BRPI0814644A2 (pt) Anticorpos para cd200 e usos destes na inibição de respostas imunes.
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
IN2012DN02345A (es)
CO2020002989A2 (es) Ácidos nucleicos estabilizados que codifican el ácido ribonucleico mensajero (arnm)
BRPI0909566A2 (pt) Linhagem de h. Polymorpha recombinante, processo de elaboração de etanol que compreende o cultivo da linhagem de h. Polymorpha recombinante e ácido nucleico recombinante
AR088647A1 (es) Metodo para reducir el estres abiotico en la planta
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
PE20150889A1 (es) Protozoo modificado que expresa al menos dos proteinas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y metodos
WO2012145582A3 (en) Methods and compositions for the specific inhibitions of egfr by double-stranded rna

Legal Events

Date Code Title Description
FG Grant, registration